Jazz Pharmaceuticals (JAZZ) Stock Rating Reaffirmed by Wells Fargo & Co

Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “buy” rating reissued by investment analysts at Wells Fargo & Co in a research note issued on Monday.

A number of other research firms also recently commented on JAZZ. FBR & Co initiated coverage on Jazz Pharmaceuticals in a report on Thursday, October 19th. They issued a “buy” rating and a $206.00 price objective on the stock. Royal Bank of Canada dropped their price objective on Jazz Pharmaceuticals from $210.00 to $195.00 and set an “outperform” rating on the stock in a report on Wednesday, November 8th. Cantor Fitzgerald reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Tuesday, August 29th. Goldman Sachs Group initiated coverage on Jazz Pharmaceuticals in a research report on Thursday, September 28th. They issued a “neutral” rating and a $165.00 target price for the company. Finally, UBS Group reissued a “buy” rating and issued a $172.00 target price (down from $175.00) on shares of Jazz Pharmaceuticals in a research report on Monday, September 25th. Two analysts have rated the stock with a sell rating, five have given a hold rating and nineteen have assigned a buy rating to the stock. Jazz Pharmaceuticals currently has an average rating of “Buy” and an average target price of $181.28.

Jazz Pharmaceuticals (NASDAQ JAZZ) opened at $135.27 on Monday. Jazz Pharmaceuticals has a 1-year low of $106.65 and a 1-year high of $163.75. The company has a market capitalization of $7,960.00, a PE ratio of 22.29, a PEG ratio of 0.86 and a beta of 0.97. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.10 and a quick ratio of 2.94.

In other Jazz Pharmaceuticals news, Director Patrick G. Enright sold 9,000 shares of the stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $139.73, for a total transaction of $1,257,570.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Iain Mcgill sold 8,000 shares of the stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $133.42, for a total value of $1,067,360.00. Following the sale, the senior vice president now directly owns 28,383 shares of the company’s stock, valued at $3,786,859.86. The disclosure for this sale can be found here. Insiders have sold a total of 18,552 shares of company stock valued at $2,549,643 over the last ninety days. 4.30% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the business. Toronto Dominion Bank lifted its holdings in shares of Jazz Pharmaceuticals by 12.4% in the 2nd quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock valued at $114,000 after buying an additional 81 shares during the period. US Bancorp DE lifted its holdings in shares of Jazz Pharmaceuticals by 94.4% in the 2nd quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock valued at $118,000 after buying an additional 368 shares during the period. Brighton Jones LLC acquired a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at approximately $213,000. SG Americas Securities LLC lifted its holdings in shares of Jazz Pharmaceuticals by 13.0% in the 2nd quarter. SG Americas Securities LLC now owns 1,384 shares of the specialty pharmaceutical company’s stock valued at $215,000 after buying an additional 159 shares during the period. Finally, Advisor Group Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 62.4% in the 3rd quarter. Advisor Group Inc. now owns 1,431 shares of the specialty pharmaceutical company’s stock valued at $210,000 after buying an additional 550 shares during the period. 90.73% of the stock is owned by institutional investors.

WARNING: This article was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.com-unik.info/2017/12/27/jazz-pharmaceuticals-jazz-stock-rating-reaffirmed-by-wells-fargo-co.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

What are top analysts saying about Jazz Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Jazz Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit